Conferences
Breast Cancers
GI Cancers
Gynecologic Cancer
Immunology News
Multiple Myeloma
Hematology
Lymphoma
Head and Neck
Lung Cancers
Melanoma
Prostate Cancer
Kidney Cancer
CLL
Precision Medicine
Supportive Care
Soft Tissue Sarcoma
More...
Giants Cancer Care

Ovarian Cancer Subtypes May Predict Response to Bevacizumab

Sean Dowdy, MD
Published Online: Monday, June 9, 2014


Sean Dowdy, MD, a Mayo Clinic gynecologic oncologist discusses a study showing molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found.



Online CME Activities
Free CME from PER
Medical Crossfire®: Mutational Testing Through Multiple Lines of NSCLC Therapy
13th Annual School of Breast Oncology® Online
Cancer Summaries and Commentaries™: Update from Orlando: Advances in Non-Hodgkin Lymphoma
Cancer Summaries and Commentaries™: Update From Orlando: Advances in Myeloproliferative Neoplasms
More Reading
 
$auto_registration$